Topikal Retinoidler: Tazaroten
Özet
Tazaroten, aktif formu olan tazarotenik asite hidrolize olan sentetik bir asetilenik retinoiddir. Tazaroten, plak psoriasisli hastalarda tek başına veya daha sıklıkla topikal kortikosteroidler, kalsipotriyol veya UV ışık tedavisi ile birlikte, hafif ve orta şiddetli akne tedavisinde tek başına ya da diğer akne topikal tedavi ajanlarıyla birlikte kullanılmış ve kombine uygulamalarda etkinliğin arttığı gösterilmiştir. Tazaroten topikal retinoidlerin kullanıldığı iktiyoz, mikozis fungoides ve diğer deri hastalıklarında da etkin bir tedavi alternatifi olarak pratik uygulamalarda yer bulmaktadır.
Referanslar
Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol. 2005;6(4):255-272.
Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009; 5(2):195-210.
Reddy V, Myers B, Yang EJ, Bhutani T. Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults. Clin Cosmet Investig Dermatol. 2020; 13:391-398.
Lotti T, Wollina U, Abdelmaksoud A, Grabbe S, Goldust M. Selective RAR agonists for acne vulgaris: A narrative review. J Cosmet Dermatol. 2020;19(6):1278-1283.
Maiti R, Sirka CS, Ashique Rahman MA, Srinivasan A, Parida S, Hota D. Efficacy and safety of tazarotene 0.1% plus clindamycin 1% gel versus adapalene 0.1% plus clindamycin 1% gel in facial acne vulgaris: a randomized, controlled clinical trial. Clin Drug Investig 2017;37(11):1083-1091.
Besner Morin C, Roberge D, Turchin I, Petrogiannis-Haliotis T, Popradi G, Pehr K. Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-Cell lymphoma. J Cutan Med Surg. 2016;20(3):244-8.
Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol 2012;148(5):592-6.
Kundu RV, Garg A, Worobec SM. Lamellar ichthyosis treated with tazarotene 0.1% gel. J Am Acad Dermatol. 2006;55(5 Suppl): S94-5.
Menzies S, Mc Menamin M, Barry R. Lentigo maligna successfully treated with combination therapy of topical tazarotene and imiquimod. Clin Exp Dermatol. 2017; 42(4):468-470.
Roeder A, Schaller M, Schäfer-Korting M, Korting HC. Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol. 2004; 17(3):111-8.
Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 1998; 39(4 Pt 2): S124-8.
Chandraratna RA. Tazarotene-first of a new generation of reseptor — selective retinoids. Br J Dermatol. 1996; 135 Suppl 49:18-25.
Tang-Liu DD-S, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999; 37(4):273-87.
Heath MS, Sahni DR, Curry ZA, Feldman SR. Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opin Drug Metab Toxicol. 2018; 14(9):919-927.
Tanghetti E, Lebwohl M, Stein Gold L. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy. J Drugs Dermatol. 2018; 17(12):1280-1287.
Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol. 1998; 39(4 Pt 2): S134-8.
Duvic M, Asans AT, Hager C, Mays S. The pathogenesis of psoriasis and mechanism of action of tazarotene. J Am Acad Dermatol. 1998t ;39(4 Pt 2): S129-33.
Asano AT, Nagpal S, Chandraratna RAS, Duvic M. Tazarotene (AGN 190168), a topical retinoid, improves psoriasis and alters epidermal gene expression in vivo. J Invest Dermatol. 1994; 58:1-90.
Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002; 6(2):95-102.
Krueger GG, Drake LA, Elias PM, Lowe NJ, Guzzo C, Weinstein GD, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psorasis. Archives Dermatol. 1998; 134(1):57-60.
Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997; 37(1):85-92
Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 2001; 40(7):468-71.
van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M. International Psoriasis Council. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol. 2011; 25(10):1130-9.
Angelo JS, Kar BR, Thomas J. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Indian J Dermatol Venereol Leprol. 2007; 73(1):65.
Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001; 40(1):64-6.
Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol. 2002; 46(6):907-13.
Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol. 1999; 140 Suppl 54:8-11.
Huang YC, Chou CL, Chiang YY. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. Lasers Surg Med. 2013; 45(2):102-7.
Koo K, Jeon C, Bhutani T. Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis. J Dermatolog Treat. 2017; 28(8):702-708.
Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. Indian J Dermatol. 2011; 56(1):40-3.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: http://www.ncbi.nlm.nih.gov/books/ NBK500668/ PubMed PMID: 29999727.
